The effectiveness and toxicity of cyclosporin a in rheumatoid arthritis: Longitudinal analysis of a population-based registry

Arthritis Care and Research

Volumn 45, Issue 3, 2001, Pages 240-245

  Marra, Carlo A ^a,b   Esdaile, John M ^a,c   Guh, Daphne ^b,c   Fisher, Janet H ^b   Chalmers, Andrew ^a   Anis, Aslam H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

Author keywords

Cyclosporin A; Pharmacoepidemiology; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTHRITIS; ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

EID: 0034795306     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200106)45:3<240::aid-art255>3.0.co;2-i     Document Type: Article

References (23)

1. Early mortality in RA predicted by poor clinical status
2. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: A 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study
3. The treatment of rheumatoid arthritis: Current trends in therapy
4. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone
5. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials
6. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
7. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine plus hydroxychloroquine, or a combination of all three medications
8. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
9. Cyclosporin
10. Cyclosporine for rheumatoid arthritis
11. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis
12. Longitudinal data analysis using generalized linear models
13. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis
14. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
15. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
16. The impact of nonsteroidal anti-inflammatory drugs on hypertension: Alternative analgesics for patients at risk
17. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis
18. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
19. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis
20. Long-term cyclosporine continuation rates in rheumatoid arthritis patients
21. Long-term efficacy and toxicity of cyclosporine A + fluocortolone + methotrexate in the treatment of rheumatoid arthritis
22. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis